Our global list of drug combinations
The following is a list of products listed by our company, which is only for medical professionals to refer to.
BYETTA （Exenatide injection)
On October 11, 2016, we have entered into an exclusive license agreement with AstraZeneca to obtain the commercial rights of Byetta and Bydureon in China, which are valid for 20 years.
|Indication||Manufacturing base||Dosage form&Dosage|
|The product is used to improve the glycemic control in patients with type 2 diabetes, which is suitable for those patients with poor glycemic control after single use of metformin, sulfonylurea or both||AstraZeneca China||
Pen injector of 5 μg dose scale: 0.25 mg/ml, 1.2 ml/piece, single injection of 5 μg, containing injection dose for 60 times;
Pen injector of 10 μg: 0.25 mg/ml, 2.4ml/piece, single injection of 10 μg, containing injection dose for 60 times.
Humulin （recombinant insulin)
On May 16, 2017, the Company signed an exclusive license agreement with Lilly China, obtaining the commercialization rights for insulin product Humulin in China.
|Indication||Manufacturing base||Dosage form & Dosage|